Search results for "BREAST"

showing 10 items of 1871 documents

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types

2020

The purpose of this study is to clinically validate a series of circulating miRNAs that distinguish between the 4 most prevalent tumor types (lung cancer (LC)

OncologyMaleLung NeoplasmsColorectal cancerlcsh:ChemistryProstate cancer0302 clinical medicinelcsh:QH301-705.5SpectroscopyEarly Detection of CancerAged 80 and over0303 health sciencesArea under the curveGeneral MedicineMiddle AgedEarly diagnosisprostate cancer3. Good healthComputer Science Applications030220 oncology & carcinogenesisArea Under CurveFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyBreast Neoplasmscolorectal cancerCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineHumansCirculating MicroRNAPhysical and Theoretical ChemistryLung cancerMolecular Biology030304 developmental biologyAgedNeoplasm StagingReceiver operating characteristicbusiness.industryOrganic ChemistryCancerProstatic Neoplasmsmedicine.diseaseCirculating MicroRNAlung cancerlcsh:Biology (General)lcsh:QD1-999ROC CurveCase-Control StudiesMultivariate Analysiscirculating microRNAsbusinessInternational Journal of Molecular Sciences
researchProduct

Detection and characterization of tumor hypoxia using pO2 histography.

2007

Data from 125 studies describing the pretreatment oxygenation status as measured in the clinical setting using the computerized Eppendorf pO2 histography system have been compiled in this article. Tumor oxygenation is heterogeneous and severely compromised as compared to normal tissue. Hypoxia results from inadequate perfusion and diffusion within tumors and from a reduced O2 transport capacity in anemic patients. The development of tumor hypoxia is independent of a series of relevant tumor characteristics (e.g., clinical size, stage, histology, and grade) and various patient demographics. Overall median pO2 in cancers of the uterine cervix, head and neck, and breast is 10 mm Hg with the ov…

OncologyMalePathologymedicine.medical_specialtyTime FactorsPhysiologyClinical BiochemistryUterine Cervical NeoplasmsBreast NeoplasmsBiochemistryInternal medicineNeoplasmsMedicineHumansOximetryStage (cooking)Neoplasm MetastasisHypoxiaMolecular BiologyGeneral Environmental ScienceTumor hypoxiabusiness.industryHistologyCell BiologyOxygenationHypoxia (medical)Tumor OxygenationPrognosisOxygenHead and Neck NeoplasmsGeneral Earth and Planetary SciencesFemaleHemoglobinmedicine.symptombusinessPerfusionSoftwareAntioxidantsredox signaling
researchProduct

Tweet this: how advocacy for breast and prostate cancers stacks up on social media.

2017

OncologyMalemedicine.medical_specialty020205 medical informaticsDatabases FactualUrologyMEDLINEBreast Neoplasms02 engineering and technology03 medical and health sciences0302 clinical medicineProstateInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineHumansSocial media030212 general & internal medicineRetrospective Studiesbusiness.industryInformation DisseminationIncidence (epidemiology)IncidenceProstatic NeoplasmsRetrospective cohort studyUnited Kingdommedicine.anatomical_structureFamily medicineFemalebusinessSocial MediaBJU international
researchProduct

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

2012

BACKGROUND: Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS: One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bical…

OncologyMalemedicine.medical_specialtyBicalutamidemedicine.drug_classVisual analogue scaleUrologyBreast painBreast painAntineoplastic AgentsAntiandrogenStatistics Nonparametriclaw.inventionTosyl CompoundsProstate cancerstomatognathic systemRandomized controlled trialBicalutamidelawInternal medicineNitrilesmedicineHumansAnilidesskin and connective tissue diseasesAgedAged 80 and overProstate cancerbusiness.industryEstrogen AntagonistsProstatic NeoplasmsMiddle Agedmedicine.diseaseAntiandrogenTamoxifenTreatment OutcomeOncologyGynecomastiaChemotherapy AdjuvantGynecomastiamedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugClinical genitourinary cancer
researchProduct

Vitamin D in cancer chemoprevention

2015

Context: There is increasing evidence that Vitamin D (Vit D) and its metabolites, besides their well-known calcium-related functions, may also exert antiproliferative, pro-differentiating, and immune modulatory effects on tumor cells in vitro and may also delay tumor growth in vivo. Objective: The aim of this review is to provide fresh insight into the most recent advances on the role of Vit D and its analogues as chemopreventive drugs in cancer therapy. Methods: A systematic review of experimental and clinical studies on Vit D and cancer was undertaken by using the major electronic health database including ISI Web of Science, Medline, PubMed, Scopus and Google Scholar. Results and conclus…

OncologyMalemedicine.medical_specialtyColorectal cancerPharmaceutical ScienceAntineoplastic AgentsBreast NeoplasmsPharmacologyChemopreventionMalignant transformationProstate cancerImmune systemBreast cancerInternal medicineNeoplasmsDrug DiscoverymedicineVitamin D and neurologyAnimalsHumansImmunologic FactorsVitamin DPharmacologyClinical Trials as TopicCancer preventionbusiness.industryCancerProstatic NeoplasmsGeneral Medicinemedicine.diseaseCancer cancer prevention calcitriol vitamin D vitamin D analoguesGrowth InhibitorsComplementary and alternative medicineSettore BIO/14 - FarmacologiaMolecular MedicineFemalebusinessColorectal Neoplasms
researchProduct

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …

OncologyMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaClinical BiochemistryAntineoplastic AgentsBone NeoplasmsAntibodies Monoclonal HumanizedZoledronic AcidMetastasisProstate cancerBreast cancerInternal medicineDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyBiologyPharmacologyDiphosphonatesbusiness.industrybone metastasis breast cancer denosumab prostate cancer skeletal-related events solid tumorsRANK LigandImidazolesBone metastasismedicine.diseaseSurgeryZoledronic acidDenosumabTreatment OutcomeMonoclonalPractice Guidelines as TopicHuman medicineDenosumabbusinessRANKL InhibitorEngineering sciences. Technologymedicine.drugExpert opinion on biological therapy
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

2013

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospe…

OncologyNon-Clinical Medicinemedicine.medical_treatmentCancer Treatmentlcsh:MedicineEstrogen receptorBioinformaticsMetastasisSurveys and QuestionnairesPathologylcsh:ScienceMultidisciplinaryMolecular pathologyCancer Risk FactorsHormonal TherapyObstetrics and GynecologyEndocrine TherapyMiddle AgedOncologyReceptors EstrogenCohortMedicineFemaleRisk assessmentMolecular PathologyResearch ArticleAdultmedicine.medical_specialtyAntineoplastic Agents HormonalGenetic Causes of CancerClinical Decision-MakingBreast NeoplasmsRisk AssessmentBreast cancerDiagnostic MedicineInternal medicineBreast CancermedicineHumansAgedRetrospective StudiesChemotherapyHealth Care Policybusiness.industryGene Expression Profilinglcsh:RHealth Risk AnalysisRetrospective cohort studyChemotherapy and Drug Treatmentmedicine.diseaselcsh:QbusinessGeneral PathologyPLoS ONE
researchProduct

Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

2012

Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzedthe association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative breast cancer patients.Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological g…

OncologyPathologyB CellsEpidemiology610 MedizinEstrogen receptorlcsh:MedicineMetastasis610 Medical sciencesBasic Cancer ResearchPathologyStage (cooking)lcsh:ScienceUnivariate analysisMultidisciplinaryHazard ratioObstetrics and GynecologyMiddle AgedImmunohistochemistryOncologyMedicineFemaleResearch Articlemedicine.medical_specialtyImmune CellsImmunoglobulinsBreast NeoplasmsDisease-Free SurvivalImmunoglobulin kappa-ChainsBreast cancerDiagnostic MedicineInternal medicineProgesterone receptorBreast CancermedicineHumansAntibody-Producing CellsSurvival analysisImmune Evasionbusiness.industrylcsh:RImmunitymedicine.diseaseConfidence intervalBiomarker EpidemiologyHumoral Immunitylcsh:QClinical ImmunologybusinessBiomarkersGeneral Pathology
researchProduct

New methods to improve the safety assessment of cryopreserved ovarian tissue for fertility preservation in breast cancer patients

2015

Objective To develop a novel molecular panel of markers to detect breast cancer (BC) disseminated malignant cells in ovarian tissue, and to improve the safety of ovarian tissue transplantation. Design Experimental study. Setting University hospital. Patient(s) Ten ovarian biopsies from healthy patients, 13 biopsies with diagnosed BC metastasis, and 4 biopsies from primary BC tumor for designing a diagnostic panel of BC cell contamination; 60 ovarian biopsies from BC patients undergoing fertility preservation for validating the panel. Animal(s) Female nude mice. Intervention(s) A novel panel for BC malignant cell detection by reverse-transcription polymerase chain reaction (RT-PCR), inmmunoh…

OncologyPathologyBiopsyMetastasisPregnancyRisk FactorsMedicineOvarian tissue cryopreservationFertility preservationMUC1Ovarian Neoplasmsmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMammaglobin AFertility PreservationObstetrics and GynecologyMiddle AgedImmunohistochemistrymedicine.anatomical_structureNeoplasm MicrometastasisHeterograftsFemaleInfertility FemaleAdultmedicine.medical_specialtyReproductive Techniques AssistedMice NudeBreast NeoplasmsOvaryBreast cancerPredictive Value of TestsInternal medicineBiopsyBiomarkers TumorAnimalsHumansNeoplasm InvasivenessAgedGlycoproteinsCryopreservationbusiness.industryOvaryMucinsMembrane Transport ProteinsReproducibility of Resultsmedicine.diseaseTransplantationFertilityReproductive MedicineCase-Control StudiesCarrier ProteinsbusinessFertility and Sterility
researchProduct